by
Barbara Kram, Editor | November 04, 2009
Merck merges with Schering
Operations begin today for the combined Merck and Schering-Plough pharmaceutical company, doing business as Merck (MRK).
The companies are already partners in pill form since they co-market cholesterol drugs Vytorin and Zetia. Now the corporate structure completes the formulation.
Schering is also known for its rheumatoid arthritis drugs.
Ad Statistics
Times Displayed: 45437
Times Visited: 1357 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The $41 billion-plus transaction came after a go-ahead from regulators in China and Mexico. Each Merck common share will automatically become a common share of the newly combined company.
The news follows closely on the heels of another mega merger in big pharma of Pfizer and Wyeth. (See DM 10489.)
Read more about it:
Merck to Buy Schering-Plough for $41.1 Billion
www.dotmed.com/news/story/8419
